A Study of WJ05129 in Advanced Malignant Solid Tumors

NCT05326035 on ClinicalTrials.gov Phase 1/2 Suzhou Junjing BioSciences Co., Ltd. (industry) Started 2022-04-19 Terminated

Riskier than 44% of active trials

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (257 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

How it ended

Terminated on 2023-12-26, after 2022-04-19 start.

Reason given by the sponsor: “business”

The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.

Termination over time, as the model saw it at the start

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-12-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: metastaticsolidstagetumorscell
Phrases that lowered it: hcvefficacydiseasesrnaclinical
Accepts healthy volunteers: No (raises risk) · Who can join
Phase: 1/2 (raises risk) · Design
Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
Has a data monitoring committee: not given (lowers risk) · Design
Design: parallel (raises risk) · Design
Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
Drug's FAERS reports with a death: 18.9% (lowers risk) · Drug's FDA history
Maximum age: 75 (lowers risk) · Who can join
Disease area, cancer: No (lowers risk) · Disease area
Minimum age: 18 (raises risk) · Who can join
Drug's FAERS reports marked serious: 94.9% (raises risk) · Drug's FDA history
Sponsor type: industry (lowers risk) · Sponsor's track record
Primary purpose: treatment (raises risk) · Design
Collaborators: 1 (raises risk) · Design
Drug's FAERS reports in the prior 12 months: 8837 (lowers risk) · Drug's FDA history
Number of arms: 2 (raises risk) · Design
Blinding: none (raises risk) · Design
Drug's FAERS reports before start: 72313 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase: 1/2 (typical: 2)
Number of arms: 2
Allocation: non randomized (typical: randomized)
Design: parallel
Primary purpose: treatment
Blinding: none
Has a data monitoring committee: not given (typical: 56% yes)
Responsible party: sponsor
Collaborators: 1 (typical: 0)
Keywords listed: 0 (typical: 1)

Who can join

Minimum age: 18
Maximum age: 75 (typical: 71)
Sex: all
Accepts healthy volunteers: No (typical: 9% yes)

Sponsor's track record

Sponsor type: industry (typical: academic or other)
Sponsor's past trials: 0 (typical: 32)
Sponsor's past termination rate: no earlier finished trials (typical: 9.9%)
Trials the sponsor started in the prior 2 years: 2 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history: 1
Drug has FAERS history: Yes (typical: 64% yes)
Drug's FAERS reports before start: 72313 (typical: 2148)
Drug's FAERS reports in the prior 12 months: 8837 (typical: 412.5)
Drug's FAERS reports marked serious: 94.9% (typical: 85.6%)
Drug's FAERS reports with a death: 18.9% (typical: 15.9%)

Disease area and drugs

Disease areas: none of the 14 tracked areas
Drugs matched to FDA substances: paclitaxel

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors NCT05155722 · started 2020 · scored riskier than 18% of active trials completed
A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors NCT05470933 · started 2022 · scored riskier than 18% of active trials terminated
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer NCT06897579 · started 2025 · scored riskier than 51% of active trials terminated
An Phase I Study of YY001 in Patients with Advanced Solid Tumors NCT06228846 · started 2022 · scored riskier than 22% of active trials completed
To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors NCT05879627 · started 2023 · scored riskier than 21% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.